Table 1 Characteristics of patients with severe asthma and the effects of biologic therapy.
No. | Age/sex | Drug | FEV1 (pred %) | ACT score | Blood eosinophils (cells/µL) | Number of exacerbations | OCS maintenance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 M | 1 M | 6 M | 0 M | 1 M | 6 M | 0 M | 1 M | 6 M | Prev.6 months | During treatment | Before treatment | During treatment | |||
1 | 43/F | Mepolizumab | 46 | 60 | 60 | 11 | 12 | 20 | 2856 | 103 | 30 | 9 | 1 | No | N/A |
2 | 74/F | Mepolizumab | 58 | 75 | 73 | 25 | 25 | 25 | 682 | 70 | 50 | 0 | 0 | No | N/A |
3 | 50/F | Reslizumab | 59 | 85 | 85 | 18 | 10 | 24 | 509 | 50 | 46 | 0 | 0 | No | N/A |
4 | 62/F | Reslizumab | 49 | 46 | 73 | 19 | 19 | 21 | 929 | 166 | 20 | 5 | 0 | No | N/A |
5 | 74/F | Dupilumab | 53 | 59 | 53 | 20 | 20 | 24 | 482 | 400 | 284 | 0 | 0 | No | N/A |
6 | 58/M | Dupilumab | 65 | 87 | 86 | 16 | 21 | 25 | 312 | 1794 | 252 | 13 | 0 | Yes | Withdrawal |
7 | 62/M | Dupilumab | 30 | 37 | 33 | 18 | 21 | 20 | 283 | 598 | 552 | 0 | 1 | Yes | No withdrawal |
8 | 46/M | Dupilumab | 73 | 99 | 90 | 13 | 22 | 24 | 202 | 2232 | 1782 | 1 | 0 | Yes | Withdrawal |
